دورية أكاديمية
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): 'Real World' Experience
| العنوان: | Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): 'Real World' Experience |
|---|---|
| المؤلفون: | Bakaloudi, Dimitra Rafailia, Talukder, Rafee, Lin, Genevieve Ihsiu, Makrakis, Dimitrios, Diamantopoulos, Leonidas N, Tripathi, Nishita, Agarwal, Neeraj, Zakopoulou, Roubini, Bamias, Aristotelis, Brown, Jason R, Pinato, David J, Korolewicz, James, Jindal, Tanya, Koshkin, Vadim S, Murgić, Jure, Miletić, Marija, Frobe, Ana, Johnson, Jeffrey, Zakharia, Yousef, Drakaki, Alexandra, Rodriguez-Vida, Alejo, Rey-Cárdenas, Macarena, Castellano, Daniel, Buznego, Lucia Alonso, Duran, Ignacio, Carballeira, Clara Castro, Barrera, Rafael Morales, Marmorejo, David, McKay, Rana R, Stewart, Tyler, Gupta, Shilpa, Ruplin, Andrew Thomas, Yu, Evan Y, Khaki, Ali R, Grivas, Petros |
| المساهمون: | Bakaloudi, Dimitra Rafailia, Talukder, Rafee, Lin, Genevieve Ihsiu, Makrakis, Dimitrio, Diamantopoulos, Leonidas N, Tripathi, Nishita, Agarwal, Neeraj, Zakopoulou, Roubini, Bamias, Aristoteli, Brown, Jason R, Pinato, David J, Korolewicz, Jame, Jindal, Tanya, Koshkin, Vadim S, Murgić, Jure, Miletić, Marija, Frobe, Ana, Johnson, Jeffrey, Zakharia, Yousef, Drakaki, Alexandra, Rodriguez-Vida, Alejo, Rey-Cárdenas, Macarena, Castellano, Daniel, Buznego, Lucia Alonso, Duran, Ignacio, Carballeira, Clara Castro, Barrera, Rafael Morale, Marmorejo, David, Mckay, Rana R, Stewart, Tyler, Gupta, Shilpa, Ruplin, Andrew Thoma, Yu, Evan Y, Khaki, Ali R, Grivas, Petros |
| سنة النشر: | 2023 |
| المجموعة: | Università degli Studi del Piemonte Orientale: CINECA IRIS |
| مصطلحات موضوعية: | Anti-PD(L)1, Bladder cancer, Immune Checkpoint Inhibitor, Immunotherapy, Urinary tract cancer |
| الوصف: | Background: Platinum-based chemotherapy (PBC) followed by avelumab switch maintenance in nonprogressors is standard first line (1L) treatment for advanced urothelial carcinoma (aUC). We describe clinical features and outcomes in a "real-world' cohort treated with avelumab maintenance for aUC. Materials and methods: This was a retrospective cohort study of patients (pts) who received 1L switch maintenance avelumab after no progression on PBC for aUC. We calculated progression-free survival (PFS) and overall survival (OS) from initiation of maintenance avelumab. We also described OS and PFS for specific subsets using Cox regression and observed response rate (ORR). Results: A total of 108 pts with aUC from 14 sites treated with maintenance avelumab were included. There was a median of 6 weeks1-30 from end of PBC to avelumab initiation; median follow-up time from avelumab initiation was 8.8 months (1-42.7). Median [m]PFS was 9.6 months (95%CI 7.5-12.1) and estimated 1-year OS was 72.5%. CR/PR (vs. SD) to 1L PBC (HR = 0.33, 95% CI 0.13-0.87) and ECOG PS 0 (vs. ≥1), (HR = 0.15, 95% CI 0.05-0.47) were associated with longer OS. The presence of liver metastases was associated with shorter PFS (HR = 2.32, 95% CI 1.17-4.59). ORR with avelumab maintenance was 28.7% (complete response 17.6%, partial response 11.1%), 29.6% stable disease, 26.9% progressive disease as best response (14.8% best response unknown). Conclusions: Results seem relatively consistent with findings from JAVELIN Bladder100 trial and recent "real world" studies. Prior response to platinum-based chemotherapy, ECOG PS 0, and absence of liver metastases were favorable prognostic factors. Limitations include the retrospective design, lack of randomization and central scan review, and possible selection/confounding biases. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/37414620; journal:CLINICAL GENITOURINARY CANCER; https://hdl.handle.net/11579/159485Test |
| DOI: | 10.1016/j.clgc.2023.06.008 |
| الإتاحة: | https://doi.org/10.1016/j.clgc.2023.06.008Test https://hdl.handle.net/11579/159485Test |
| رقم الانضمام: | edsbas.8C08652F |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.clgc.2023.06.008 |
|---|